MDHPH primarily acts as a reuptake inhibitor at monoamine transporters; it exerts its effect by blocking the dopamine transporter (DAT) and the noradrenaline transporter (NET).
In vitro studies on synaptosomes from rat brains show strong inhibition of DAT (IC50 value: 8.4 ± 2.2 nM) and NET ( comprar mdphp , mdphp para venda ), leading to increased extracellular concentrations of dopamine and norepinephrine due to the inhibition of reuptake. This transporter blockade distinguishes MDHPH from substrate-like releasers such as amphetamines, as it does not exhibit significant activity as a transporter substrate but rather competitively inhibits reuptake without inducing efflux.
Pharmacodynamics :
The affinity for the serotonin transporter ( buy mdphp , buy mdphp , order mdphp ) is significantly lower; weak to moderate inhibition was observed (IC50 > 1 μM in comparable tests), which contributes to minimal serotonergic modulation compared to dopaminergic and noradrenergic potency.
Unlike entactogens such as mdphp, MDPHP does not exhibit significant agonism at monoamine receptors (e.g., at the "Trace Amine-Associated Receptor 1" or at serotonin receptors); its stimulating profile results exclusively from the reuptake inhibition and the subsequent synaptic accumulation of catecholamines.
Compared to its structurally related analogue MDPV, MDPHP exhibits a similarly high-affinity DAT blockade (MDPV IC50 = 4.1 ± 0.5 nM), but lower potency at the NET ( MDPHP vs. MDPV IC50 = 26 ± 8 nM). This underscores a common mechanism of action within the class of methylenedioxycopene ( a group of synthetic cathinones), in which catecholaminergic pathways are favored over serotonergic pathways. This selective effect of MDPHP is causally linked to downstream hyperactivation of adrenergic and dopaminergic pathways, which is not directly mediated via receptors.
의견을 남겨주세요